Streetbeat News

Price Targets

DGX

UBS analyst Kevin Caliendo has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $135 to $137.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:25 pm

BRZE

UBS analyst Taylor McGinnis has maintained a Neutral rating on Braze (NASDAQ:BRZE) and increased the price target from $51 to $60.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:18 pm

NAPA

The Duckhorn Portfolio's stock (NAPA) is down following disappointing Q1 financial results and FY24 revenue guidance that fell short of expectations. Additionally, B of A Securities downgraded NAPA from Buy to Neutral and reduced the price target from $15 to $11.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:17 pm

ALL

UBS analyst Brian Meredith has maintained a Buy rating on Allstate (NYSE:ALL) and increased the price target from $152 to $160.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:15 pm

MNDY

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on Monday.Com (NASDAQ:MNDY) and increased the price target from $200 to $225. This adjustment suggests a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:12 pm

IGMS

HC Wainwright & Co. analyst Robert Burns has downgraded IGM Biosciences (NASDAQ:IGMS) from Buy to Neutral and reduced the price target from $11 to $7.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:10 pm

STN

RBC Capital analyst Sabahat Khan has maintained an Outperform rating on Stantec and increased the price target from C$106 to C$118.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:06 pm

GCT

Roth MKM analyst Matt Koranda has reaffirmed a Buy rating on GigaCloud Tech (NASDAQ:GCT) and increased the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 4:05 pm

MET

Over the past quarter, MetLife (NYSE:MET) received 5 analyst ratings, with 1 bullish and 4 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The 12-month price targets for MetLife have an average of $76.4, a high of $82.00, and a low of $71.00. This average has increased by 1.53% from the previous target of $75.25. Analyst ratings are based on information from company activities, financial statements, and insider conversations, and are used to guide investors on stock performance.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 4:00 pm

NBIX

Over the past 3 months, 17 Wall Street analysts have published their opinions on Neurocrine Biosciences (NASDAQ:NBIX), with the majority being bullish or somewhat bullish. The average 12-month price target for NBIX is $130.0, with a high of $165.00 and a low of $100.00, marking a 4.84% increase from the previous target of $124.00. Analysts rate stocks based on company financials, meetings, and insider communications, typically updating their ratings quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 4:00 pm